Niacinamide

Drug Overview

Niacinamide (also known as nicotinamide or vitamin B3) is an orally bioavailable, water-soluble vitamin and a critical precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for energy metabolism and DNA repair. While most commonly known as a dietary supplement or a skincare ingredient, niacinamide has a specialized and vital role in oncology as a radiosensitizer and chemosensitizer.

In the clinical landscape of March 2026, niacinamide is recognized for its ability to modulate the tumor microenvironment, specifically by improving blood flow and reducing hypoxia (oxygen deficiency) within solid tumors. Because tumors with low oxygen levels are notoriously resistant to radiation and many types of chemotherapy, niacinamide is used as an adjunctive therapy to “prime” the tumor, making it more susceptible to destruction. It is often used in a specific protocol known as ARCON (Accelerated Radiotherapy with Carbogen and Nicotinamide).

• Generic Name: Niacinamide (Nicotinamide).
• Drug Class: Vitamin; Radiosensitizer; Chemosensitizer.
• Mechanism: Precursor to NAD+; inhibits PARP-1; reduces tumor hypoxia by preventing transient vascular “shut-downs.”
• Route of Administration: Oral (Tablet or Capsule).
• FDA Approval Status: FDA-approved as a vitamin/supplement. Its use in oncology as a radiosensitizer is typically investigational or performed under specific therapeutic protocols. It is not currently approved as a standalone “anti-cancer drug,” but rather as a support agent to enhance other treatments.

What Is It and How Does It Work? (Mechanism of Action)

Niacinamide’s anti-cancer potential stems from its influence on how cells repair their DNA and how tumors manage their blood supply.

1. Reducing Tumor Hypoxia

Solid tumors often have a “chaotic” blood supply. Some blood vessels randomly “shut down” for short periods, leaving parts of the tumor without oxygen (acute hypoxia).

• Vascular Normalization: Niacinamide helps prevent these transient vessel closures.
• The Oxygen Effect: Radiation therapy requires oxygen to create the free radicals that break cancer DNA. By ensuring the tumor stays oxygenated, niacinamide makes radiation much more effective at killing the cancer cells.

2. Inhibition of PARP-1

Niacinamide is a natural inhibitor of Poly (ADP-ribose) polymerase-1 (PARP-1), an enzyme that cancer cells use to repair single-strand DNA breaks.

• Preventing Repair: When radiation or chemotherapy damages cancer DNA, PARP-1 normally rushes in to fix it. Niacinamide interferes with this repair process, leading to the accumulation of DNA damage and the eventual death of the cancer cell (apoptosis).

3. NAD+ Replenishment

As a precursor to NAD+, niacinamide supports the metabolic health of healthy cells, potentially helping them survive the stress of cancer treatment better than the “metabolically inflexible” cancer cells.

FDA Approved Clinical Indications

There are no FDA-approved “oncology-specific” indications for niacinamide.

However, clinical research through 2026 has established its use in the following supportive settings:

• Bladder Cancer (ARCON Protocol): Used alongside radiation and carbogen (a mixture of oxygen and CO2) to improve local control of the tumor.
• Laryngeal and Head/Neck Cancers: Evaluated to see if it can reduce the need for surgery by making radiation therapy more successful.
• Skin Cancer Prevention: High-dose niacinamide (500 mg twice daily) is used to reduce the risk of Non-Melanoma Skin Cancers (basal cell and squamous cell carcinoma) in high-risk patients.
• Glioblastoma (Brain Cancer): Investigated as a chemosensitizer to improve the effectiveness of Temozolomide.

Dosage and Administration Protocols

In oncology, niacinamide is used in much higher doses than those found in a standard multivitamin.

Clinical Efficacy and Research Results

As of early 2026, the data on niacinamide has been bolstered by long-term prevention studies:

• The ONTRAC Study: This landmark trial confirmed that niacinamide 500 mg BID reduced the rate of new non-melanoma skin cancers by 23% in high-risk individuals.
• ARCON Bladder Results: Clinical data from 2024–2025 indicated that the ARCON protocol (including niacinamide) improved regional control of bladder cancer by nearly 15% compared to radiation alone.
• Neuroprotection Research: In 2026, there is emerging evidence that niacinamide may help protect healthy nerve cells from the toxicity of certain chemotherapies, reducing the incidence of Peripheral Neuropathy.

Safety Profile and Side Effects

While niacinamide is generally safe, the high doses used in oncology can lead to specific side effects. Note that niacinamide does not cause the “flushing” reaction associated with nicotinic acid (niacin).

Common Side Effects (>15%):

• Gastrointestinal: Nausea, vomiting, and diarrhea, particularly at doses above 3 grams per day.
• Dizziness and Headache: Often reported shortly after the radiosensitizing dose is taken.
• Fatigue: General systemic tiredness.

Serious Risks:

• Hepatotoxicity (Liver Toxicity): Very high doses can cause elevations in liver enzymes. This is usually reversible once the drug is stopped.
• Hyperglycemia: It may slightly increase blood sugar levels, requiring careful monitoring in diabetic patients.
• Interactions: It can interfere with the clearance of certain anti-seizure medications (like carbamazepine), leading to toxic levels in the blood.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, niacinamide is being used to study “Sirtuin Activation.” Researchers are investigating how niacinamide-derived NAD+ can activate SIRT1, a “longevity gene” that helps maintain the health of Mesenchymal Stem Cells. In 2026, there is also intense focus on “Immuno-metabolism.” Scientists are exploring if niacinamide can improve the “stamina” of T-cells in the tumor microenvironment by providing them with more NAD+ for energy production. Furthermore, studies are looking into its use as a “neuro-protectant” for patients with early-stage Parkinson’s disease.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Liver Function Tests (LFTs): Baseline tests are mandatory before starting high-dose therapy.
• Blood Glucose Baseline: Especially for patients with pre-diabetes or type 2 diabetes.

“Do’s and Don’ts” List:

• DO take the medication exactly 1–2 hours before your radiation appointment if you are on a radiosensitization protocol; timing is critical for the “oxygen effect.”
• DO report any yellowing of the skin or eyes (jaundice) immediately to your oncology team.
• DON’T confuse niacinamide with “niacin” (nicotinic acid). Niacin can cause severe skin flushing and has a different effect on the body.
• DON’T take over-the-counter niacinamide supplements in addition to your prescribed dose without consulting your oncologist, as toxicity is dose-dependent.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Niacinamide is a vitamin supplement and is not intended to diagnose, treat, cure, or prevent cancer as a standalone therapy. Always consult with your oncology team before starting high-dose niacinamide, especially as part of a radiation or chemotherapy protocol.